Documents - Marketing authorisation medicines for human use

51 documents Marketing authorisation medicines for human use

Enter search criteria

Fill in keyword(s) to narrow your search.

Fill in a starting date and a closing date for the period your query is about: DD-MM-YYYY

You can select a specific type of a document or publication you are looking for, such as press releases or speeches.

Only subscribe to documents from this organisation

Explanation of the Interest Form - MEB-ZIN Parallel Procedures pilot

Accelerating patient access to reimbursable innovative medicines has been on the wish list of the government, patient ...

Publication | 10-07-2019

List of patient-friendly terms for the package leaflet

In order to optimise the readability of the package leaflet, the MEB has revised the list of patient-friendly terms. The list has ...

Policy document | 28-06-2019

MEB 13: Nomenclature of pharmaceutical products

This document describes the requirements which the marketing authorisation holder has to fulfil when submitting a proposal for a ...

Policy document | 10-05-2019

MEB 21: Statement of ‘abbreviated indications’ on OTC medicinal product packaging

Directive 2001/83/EC discusses European regulations on labelling. In accordance with Article 54(n), the outer packaging of ...

Policy document | 10-05-2019

Declaration on modification of information in the printed SmPC and package leaflet pertaining to patented indications

Form | 01-05-2019

Product types and fees

The list of product types indicates the various product types handled by the MEB. The choice of the product type determines the ...

Publication | 01-01-2019

Scientific advice during the development of a medicinal product

The MEB can provide scientific advice and contributes with this advice to the development of medicines. See the leaflet for ...

Leaflet | 01-01-2019

MEB 14: Parallel importation: marketing authorisation and maintenance

Parallel import is the importation – and subsequent marketing in the Netherlands – of a medicinal product authorised elsewhere in ...

Policy document | 08-11-2018

Question and answer document concerning changes not covered by the Variation Regulation 1234/2008 (as amended by Regulation 712/2012)

Policy document | 05-10-2018

Letter to stakeholders regarding the implementation of safety features under the Falsified Medicines Directive 2011/62/EU

The delegated Regulation on the characteristics of the safety features and the new medicine verification system will apply as of ...

Publication | 01-10-2018